Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Rang in Aktien
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Aktienkurs
$4.48
Marktkapitalisierung
$4.99B
Veränderung (1 Tag)
-5.20%
Veränderung (1 Jahr)
-41.89%
Land
CN
Handel Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Kategorie
Healthcare
Operative Marge für Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Operative Marge zum October 2026 TTM: 10.66%
Laut den neuesten Finanzberichten und dem Aktienkurs von Shenzhen Salubris Pharmaceuticals Co., Ltd. beträgt die aktuelle operative Marge (TTM) 10.66%. Am Ende des Jahres 2024 lag die operative Marge bei 16.11%.
Historie der operativen Marge von Shenzhen Salubris Pharmaceuticals Co., Ltd. von 2006 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 10.66% | -26.94% |
| 2025 | 14.59% | -9.44% |
| 2024 | 16.11% | -17.34% |
| 2023 | 19.49% | -6.70% |
| 2022 | 20.89% | 8.97% |
| 2021 | 19.17% | 563.32% |
| 2020 | 2.89% | -84.73% |
| 2019 | 18.93% | -48.80% |
| 2018 | 36.97% | -10.44% |
| 2017 | 41.28% | -2.92% |
| 2016 | 42.52% | 0.02% |
| 2015 | 42.51% | 1.50% |
| 2014 | 41.88% | 0.72% |
| 2013 | 41.58% | 7.03% |
| 2012 | 38.85% | 27.80% |
| 2011 | 30.40% | -4.40% |
| 2010 | 31.80% | 9.96% |
| 2009 | 28.92% | 20.90% |
| 2008 | 23.92% | 9.78% |
| 2007 | 21.79% | 18.55% |
| 2006 | 18.38% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 28.37% | -97.34% |
US
|
|
| 12.36% | -98.84% |
FR
|
|
| 30.18% | -97.17% |
JP
|
|
| 9.83% | -99.08% |
US
|
|
| 9.87% | -99.07% |
CH
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.